Buffer

ANGUS ACHIEVES 2022 ECOVADIS GOLD RATING STATUS FOR SUSTAINABILITY PERFORMANCE

Retrieved on: 
Thursday, June 16, 2022

BUFFALO GROVE, Ill., June 16, 2022 /PRNewswire/ --ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty chemicals for Life Sciences and Industrial markets, today announced it was awarded the 2022 Gold Recognition Level in sustainability performance by EcoVadis.

Key Points: 
  • BUFFALO GROVE, Ill., June 16, 2022 /PRNewswire/ --ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty chemicals for Life Sciences and Industrial markets, today announced it was awarded the 2022 Gold Recognition Level in sustainability performance by EcoVadis.
  • The Gold rating places ANGUS in the 92nd percentile of the tens of thousands of global companies assessed by EcoVadis each year.
  • "We are honored to receive the EcoVadis Gold rating for our sustainability performance," said Dr. Pam Spencer, Vice President, Regulatory, Product Stewardship, Quality and Sustainability.
  • ANGUS invites its commercial partners to request direct access to ANGUS' 2022 evaluation results from EcoVadis as part of their supplier evaluation process.

Spectrum Chemical Enters into New Distribution Arrangement with ANGUS Chemical Company to Provide Select TRIS Buffers and Derivatives for Life Sciences and Biopharmaceuticals Markets in United States and Canada

Retrieved on: 
Thursday, June 9, 2022

Today, ANGUS is the worlds largest and only fully integrated manufacturer of TRIS buffers.

Key Points: 
  • Today, ANGUS is the worlds largest and only fully integrated manufacturer of TRIS buffers.
  • We are committed to delivering the fullest range of high-quality chemicals necessary for every bioprocessing stage, from development through commercialization.
  • Luchsinger pointed out that the new ANGUS-branded products also complement Spectrum Chemicals current bioprocessing portfolio such as its bioCERTIFIED product line .
  • Spectrum Chemical supplies hundreds of unique cell culture additives in a wide range of packaging sizes throughout the world.

Freecoat Nails Names Carisa Findley as President

Retrieved on: 
Wednesday, June 1, 2022

CHARLOTTE, N.C., June 1, 2022 /PRNewswire/ -- freecoat nails, one of the nation's leading non-toxic nail and beauty franchises, announces today that best-selling author and renowned international motivational speaker, Carisa Findley, has joined as the new President.

Key Points: 
  • CHARLOTTE, N.C., June 1, 2022 /PRNewswire/ -- freecoat nails, one of the nation's leading non-toxic nail and beauty franchises, announces today that best-selling author and renowned international motivational speaker, Carisa Findley, has joined as the new President.
  • With her inspirational and motivational approach, Findley went on to deliver keynote speeches built on mindfulness practices and motivational techniques.
  • Blending her personal style fueled with a passion for business development, health & wellness, nutrition, meditation, and mindfulness, Findley joins freecoat nails as the brand's first President.
  • "Kat and I are super excited and proud to welcome Carisa to the freecoat family," said Landon Eckles, co-owner and CEO of freecoat.

Univar Solutions and ANGUS Expand Distribution Agreement in Europe to Include the Homecare & Industrial Cleaning Market

Retrieved on: 
Wednesday, May 25, 2022

ROTTERDAM, Netherlands, May 25, 2022 /PRNewswire/ -- Europe, Univar B.V., a subsidiary of Univar Solutions Inc. (NYSE: UNVR) ("Univar Solutions" or "the Company"), a leading global commodity and specialty chemical and ingredient distributor and provider of value-added services, announced today the expansion of its distribution agreement with ANGUS Chemical Company ("ANGUS"), a leading global manufacturer of specialty chemicals for life sciences, home and personal care and industrial markets, to include the pan-European Homecare & Industrial Cleaning (HIC) market. This agreement will further enable Univar Solutions to provide its customers with expanded access to specialty cleaning ingredients alongside comprehensive technical innovation and sourcing support.

Key Points: 
  • This agreement will further enable Univar Solutions to provide its customers with expanded access to specialty cleaning ingredients alongside comprehensive technical innovation and sourcing support.
  • Under the expanded agreement, Univar Solutions will also offer ULTRA PC-grades of ANGUS amino alcohols for homecare and industrial cleaning customers who seek low secondary amine content.
  • "At Univar Solutions, we support homecare and industrial cleaning manufacturers around the globe through a hub-and-spoke model of Solution Centers offering prototyping, trend kits, performance and raw material evaluations and formulation as well as technical assistance," said Aaron Lee, global vice president for Homecare & Industrial Cleaning at Univar Solutions.
  • "We are excited to expand our existing agreement with Univar Solutions and their broad network and deep expertise in homecare and industrial cleaning applications to better serve formulators and manufacturers across Europe that are using ANGUS chemistries."

Univar Solutions and ANGUS Expand Distribution Agreement in Europe to Include the Homecare & Industrial Cleaning Market

Retrieved on: 
Wednesday, May 25, 2022

ROTTERDAM, Netherlands, May 25, 2022 /PRNewswire/ -- Europe, Univar B.V., a subsidiary of Univar Solutions Inc. (NYSE: UNVR) ("Univar Solutions" or "the Company"), a leading global commodity and specialty chemical and ingredient distributor and provider of value-added services, announced today the expansion of its distribution agreement with ANGUS Chemical Company ("ANGUS"), a leading global manufacturer of specialty chemicals for life sciences, home and personal care and industrial markets, to include the pan-European Homecare & Industrial Cleaning (HIC) market. This agreement will further enable Univar Solutions to provide its customers with expanded access to specialty cleaning ingredients alongside comprehensive technical innovation and sourcing support.

Key Points: 
  • This agreement will further enable Univar Solutions to provide its customers with expanded access to specialty cleaning ingredients alongside comprehensive technical innovation and sourcing support.
  • Under the expanded agreement, Univar Solutions will also offer ULTRA PC-grades of ANGUS amino alcohols for homecare and industrial cleaning customers who seek low secondary amine content.
  • "At Univar Solutions, we support homecare and industrial cleaning manufacturers around the globe through a hub-and-spoke model of Solution Centers offering prototyping, trend kits, performance and raw material evaluations and formulation as well as technical assistance," said Aaron Lee, global vice president for Homecare & Industrial Cleaning at Univar Solutions.
  • "We are excited to expand our existing agreement with Univar Solutions and their broad network and deep expertise in homecare and industrial cleaning applications to better serve formulators and manufacturers across Europe that are using ANGUS chemistries."

Teknova to Participate in Upcoming Investor Conference

Retrieved on: 
Wednesday, May 25, 2022

HOLLISTER, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (Teknova) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will participate in the following upcoming investor conference:

Key Points: 
  • HOLLISTER, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (Teknova) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will participate in the following upcoming investor conference:
    Stephen Gunstream, President and Chief Executive Officer, and Matt Lowell, Chief Financial Officer, will present at 4:20 p.m.
  • Gunstream and Lowell plan to discuss Company highlights, their product portfolio, market trends, key growth drivers, and long-term market opportunities.
  • The live audio webcast for this conference may be accessed from the Investor Relations section of the Companys website: https://ir.teknova.com/ .
  • Teknova is expediting clinical breakthroughs in life sciences by providing custom products and reagents for drug therapies, novel vaccines, and molecular diagnostics.

AM Best Revises Outlooks to Positive for Dubai Insurance Company (PSC)

Retrieved on: 
Friday, May 20, 2022

The assessment factors in the companys sufficient liquidity and prudent reserving, which incorporates buffers over the actuarial best estimate.

Key Points: 
  • The assessment factors in the companys sufficient liquidity and prudent reserving, which incorporates buffers over the actuarial best estimate.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Bests Credit Ratings .
  • AM Best is a global credit rating agency, news publisher and data analytics provider specialising in the insurance industry.
  • Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City.

Teknova Reports First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, May 11, 2022

HOLLISTER, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2022.

Key Points: 
  • Gross profit for the first quarter 2022 was $5.3 million, compared to $5.0 million in the first quarter 2021.
  • Gross margin for the first quarter 2022 was 48.0% of revenue, compared to 55.4% in the first quarter 2021.
  • Operating expenses for the first quarter 2022 were $11.2 million, compared to $5.9 million in the first quarter 2021.
  • The increase also reflects costs in the first quarter 2022 associated with operating as a public company when compared to the first quarter 2021.

Teknova to Report First Quarter 2022 Financial Results on May 11, 2022

Retrieved on: 
Wednesday, May 4, 2022

HOLLISTER, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (Teknova) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2022, on Wednesday, May 11, 2022, following the close of market.

Key Points: 
  • HOLLISTER, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (Teknova) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2022, on Wednesday, May 11, 2022, following the close of market.
  • Teknova will host a webcast and conference call on Wednesday, May 11, 2022, beginning at 4:30 p.m.
  • Participants can access the live webcast on the Investor Relations section of the Teknova website and at this link: https://edge.media-server.com/mmc/p/6nk6u95b .
  • Teknova is expediting clinical breakthroughs in life sciences by providing custom products and reagents for drug therapies, novel vaccines, and molecular diagnostics.

Research Antibodies Market - Global Forecasts from 2022 to 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 29, 2022

The "Global Research Antibodies Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Research Antibodies Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Research Antibodies market was valued at US$3.581 billion in 2020 and is expected to grow at a CAGR of 7.00% over the forecast period to reach a total market size of US$5.751 billion by 2027.
  • Powered by the increasing demand for tailored medicine and structure-based drug design, the global market for research antibodies is expected to grow rapidly over the next few years.
  • Research and development activities to develop novel vaccines and treatments have prompted a substantial increase in the demand for research antibodies.